v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash $ 4,088,304 $ 5,353,392
Advances on research and development contract services 131,194 147,017
Prepaid insurance 55,219 49,224
Other prepaid expenses and current assets 56,099 10,380
Total current assets 4,330,816 5,560,013
Total assets 4,330,816 5,560,013
Current liabilities:    
Accounts payable and accrued expenses, including $44,972 and $46,982 to related parties at March 31, 2023 and December 31, 2022, respectively 223,631 229,764
Research and development contract liabilities 26,356 165,022
Total current liabilities 249,987 394,786
Commitments and contingencies
Stockholders’ equity:    
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 729,167 shares 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 16,659,093 shares and 16,646,593 shares at March 31, 2023 and December 31, 2022, respectively 1,665 1,664
Additional paid-in capital 45,341,522 45,058,262
Accumulated deficit (44,762,358) (43,394,699)
Total stockholders’ equity 4,080,829 5,165,227
Total liabilities and stockholders’ equity $ 4,330,816 $ 5,560,013

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL